HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Ocugen, Inc. (OCGN)
0.2212  -0.0038  (-1.69%) 07-03 15:31
Open: 0.23 High: 0.2325
Pre.close: 0.225 Low: 0.218
Volume: 5,271,473 Ave vol: 10,679,034
52w High: 17.399965 52w Low: 0.17
MA(50): 0.266 MA(200): 0.397
EPS: P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://ocugen.com
Market Cap (M): 24
Shares Out (M): 110
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Technical analysis
Overall: Neutral
MA: Bearish MACD: Bullish
KDJ: Bullish RSI: Bearish
Target 1: 0.31 Target 2: 0.37
Resist 1: 0.26 Resist 2: 0.32
Support 1: 0.17 Support 2: 0.14
Company key metrics
Revenue per Share: 0
Net Income per Share: -1.4539
Cash per Share: 0.5358
Book Value per Share: 0.793
Price to Sales: 0
Price to Book Value: 0.6809
Earnings Yield: -2.6924
Dividend Yield: 0
Debt to Equity: 0.5254
Debt to Assets: 0.3444
Financial analysis
Price to Book Value: Outperform
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Outperform
Stock Charts
Headline news
Tue, 23 Jun 2020
It’s Time Again to Look deep into books of Ocugen, Inc. (OCGN) - The News Heater

Thu, 11 Jun 2020
Do Traders View Ocugen Inc (OCGN) Stock's Current Trend Positively? - InvestorsObserver

Fri, 26 Jun 2020
Ocugen Inc. (OCGN) distance from 200-day Simple Moving Average is $1.4343: Right on the Precipice - News Daemon

Mon, 15 Jun 2020
Ocugen Inc. (OCGN) is predicted to post EPS of -0.04 in the upcoming quarter : This Stock is Ticking Every Box for Top Investors - News Daemon

Tue, 16 Jun 2020
Ocugen, Inc. (OCGN) and the Battle of Fundamental vs. Technical - The News Heater

Tue, 09 Jun 2020
Ocugen Inc. (NASDAQ:OCGN) Announce Discontinuation Of Third Phase OCU300 Trial In Treatment of oGVHD - BP Journal

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.